MedTech & Diagnostics
Penumbra Executive Compensation (FY25)
PEN · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025 ◇ Adam Elsesser | Latest say-on-pay support = June 18, 2026 | Chief executive pay ratio ◇ To the median employee |
Velarion Member: every covered company in MedTech & Diagnostics, with dashboards, peer screens and board-ready briefs. Three seats, one year.
The paid brief on Penumbra
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Data as of October 17, 2026Latest filing (8-K): June 22, 2026
16 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Member, one year
243 figures on this page: 233 cited to the filing that reported them, 10 calculated from figures it prints. See the citations
Total compensation for Adam Elsesser, Chairman, Chief Executive Officer and former President, came to $851,621 in fiscal 2025, and Elsesser's total moved 35.1% higher from the $630,467 reported for fiscal 2024. The company reported a chief executive pay ratio of 11:1 for fiscal 2025, against median employee compensation of $74,923. Shareholders supported the say-on-pay proposal with 96.9% of votes cast for or against in favor at the meeting held June 18, 2026 for fiscal 2025. The disclosed peer group names 10x Genomics, Bio-Techne, CONMED Corporation, Glaukos Corporation and Globus Medical, among others.
More on Penumbra
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Adam Elsesser: $630,467 → $851,621 (35.1% higher)
Say-on-pay support: 97.8% → 96.9% (0.9 points lower)
CEO pay ratio: 9:1 → 11:1 (22.2% higher)
Frequently asked questions
Answers drawn from the data on this page.
Who is Penumbra's chief executive and what were they paid?
Total compensation for Adam Elsesser, Chairman, Chief Executive Officer and former President, came to $851,621 in fiscal 2025. Elsesser's total moved 35.1% higher from the $630,467 reported for fiscal 2024.
What was Penumbra's say-on-pay result?
Shareholders supported the say-on-pay proposal with 96.9% of votes cast for or against in favor at the meeting held June 18, 2026 for fiscal 2025.
Which companies are in Penumbra's peer group?
The disclosed peer group names 10x Genomics, Bio-Techne, CONMED Corporation, Glaukos Corporation and Globus Medical, among others.
What is Penumbra's chief executive pay ratio?
The company reported a chief executive pay ratio of 11:1 for fiscal 2025, against median employee compensation of $74,923.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Johanna Roberts Executive Vice President, General Counsel and Secretary | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Maggie Yuen Chief Financial Officer | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Lambert Shiu Chief Accounting Officer | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Adam Elsesser Chief Executive Officer and President | ◇ | — | — | — | — | — | ◇ | ◇ |
Fiscal 2023
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Maggie Yuen Chief Financial Officer | ◇ | — | — | — | — | — | ◇ | ◇ |
Johanna Roberts Executive Vice President, General Counsel and Secretary | ◇ | — | — | — | — | — | ◇ | ◇ |
Adam Elsesser Chief Executive Officer and former President | ◇ | — | — | — | — | — | ◇ | ◇ |
Lambert Shiu Chief Accounting Officer | ◇ | — | — | — | — | — | ◇ | ◇ |
Fiscal 2024
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Johanna Roberts Executive Vice President, General Counsel and Secretary | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Maggie Yuen Chief Financial Officer | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Lambert Shiu Chief Accounting Officer | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Adam Elsesser Chief Executive Officer and former President | ◇ | — | — | — | — | — | ◇ | ◇ |
Fiscal 2025
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Shruthi Narayan President | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Maggie Yuen Chief Financial Officer | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Johanna Roberts Executive Vice President, General Counsel and Secretary | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Lambert Shiu Chief Accounting Officer | ◇ | — | ◇ | — | — | — | ◇ | ◇ |
Adam Elsesser Chairman, Chief Executive Officer and former President Departed during or after this year | ◇ | — | — | — | — | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Johanna Roberts | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Johanna Roberts | PSU | — | ◇ | ◇ | — | ◇ | — | — |
| Johanna Roberts | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Johanna Roberts | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Lambert Shiu | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Lambert Shiu | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Lambert Shiu | PSU | — | ◇ | ◇ | — | ◇ | — | — |
| Lambert Shiu | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Maggie Yuen | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Maggie Yuen | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Maggie Yuen | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Maggie Yuen | PSU | — | ◇ | ◇ | — | ◇ | — | — |
| Shruthi Narayan | PSU | — | ◇ | ◇ | — | ◇ | — | — |
| Shruthi Narayan | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Shruthi Narayan | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Shruthi Narayan | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Shruthi Narayan | RSU | ◇ | — | — | ◇ | — | — | ◇ |
Fiscal 2022 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Johanna Roberts | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Lambert Shiu | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Shruthi Narayan | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Maggie Yuen | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Severance and change in control
The terms as written in the agreements.
Adam Elsesser
Chairman, Chief Executive Officer and former President
| Change-in-control trigger | ◇ |
| Equity acceleration on change in control | ◇ |
| Excise tax treatment | ◇ |
| Clawback | ◇ |
Johanna Roberts
Executive Vice President, General Counsel and Secretary · Offer letter
| Change-in-control trigger | ◇ |
| Equity acceleration on change in control | ◇ |
| Excise tax treatment | ◇ |
| Clawback | ◇ |
Lambert Shiu
Chief Accounting Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Equity acceleration on change in control | ◇ |
Shruthi Narayan
President · Terms as described in the company’s compensation discussion · citing a 2026 filing
| Equity acceleration on change in control | ◇ |
Director compensation
What each non-employee director was paid.
Fiscal 2025
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Bridget O'Rourke | ◇ | ◇ | — | — | — | — | ◇ |
Thomas Wilder Lead independent director | ◇ | ◇ | — | — | — | — | ◇ |
Janet Leeds | ◇ | ◇ | — | — | — | — | ◇ |
Surbhi Sarna | ◇ | ◇ | — | — | — | — | ◇ |
Harpreet Grewal | ◇ | ◇ | — | — | — | — | ◇ |
Arani Bose | ◇ | ◇ | — | — | — | — | ◇ |
Arani Bose, M.D | ◇ | ◇ | — | — | — | — | ◇ |
Adam Elsesser and Don Kassing served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as restricted stock units.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
- 10x Genomics TXG
- Bio-Techne TECH
- CONMED Corporation CNMD
- Glaukos Corporation GKOS
- Globus Medical GMED
- Haemonetics Corporation HAE
- Inspire Medical Systems INSP
- Insulet Corporation PODD
- Integer Holdings ITGR
- Integra LifeSciences Holdings IART
- iRhythm Technologies IRTC
- Lantheus Holdings LNTH
- LivaNova PLC LIVN
- Masimo Corporation MASI
- Medpace Holdings MEDP
- Merit Medical Systems MMSI
- Neogen Corporation NEOG
- QuidelOrtho Corporation QDEL
- Sotera Health Company SHC
- Tandem Diabetes Care TNDM
- Teladoc Health TDOC
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2025 | June 18, 2026 | = | ◇ | ◇ | ◇ |
| 2024 | May 28, 2025 | = | ◇ | ◇ | ◇ |
| 2023 | June 5, 2024 | = | ◇ | ◇ | ◇ |
| 2022 | May 31, 2023 | = | ◇ | ◇ | ◇ |
| 2021 | June 1, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 2, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 3, 2020 | = | ◇ | ◇ | ◇ |
| 2018 | June 5, 2019 | = | ◇ | ◇ | ◇ |
| 2017 | June 6, 2018 | = | ◇ | ◇ | ◇ |
| 2016 | June 7, 2017 | = | ◇ | ◇ | ◇ |
Chief executive pay ratio
As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Velarion Pro: every company page, peer tools and exports, one seat
One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Adam Elsesser (Chairman, Chief Executive Officer and former President), FY2025 total compensation $851,621 (base salary $850,000) [exec_comp, SEC accession 0001321732-26-000010, filed 2026-04-29]What this page does not include
Everything above is a fact Penumbra disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Penumbra sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
243 figures on this page: 233 cited to the filing that reported them, 10 calculated from figures it prints.
233 cited to the filing
10 calculated from the filing
Documents cited
- 0001321732-26-000030Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001321732-26-0000102025 Director Compensation Table · 2025 Outstanding Equity Awards at Fiscal Year-End Table · 2025 Summary Compensation Table · CEO Pay Ratio · and 2 more sections
- 0001321732-25-000093Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001321732-25-0000742024 Summary Compensation Table
- 0001321732-24-000075Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001321732-24-0000522023 Summary Compensation Table
- 0001321732-23-000072Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001321732-23-000054
- 0001321732-22-000061Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001321732-21-000050Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001321732-20-000094Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001321732-20-000047Exhibit
- 0001321732-19-000068The compensation of the Company’s Named Executive Officers was approved, on an advisory basis, based on the following results of voting: Votes For Votes Against Abstentions Broker Non-Votes
- 0001321732-18-000077Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001321732-17-000124Item 5.07 Submission of Matters to a Vote of Security Holders
- 0001193125-15-291880Exhibit
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Penumbra executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/PEN (accessed 2026).
Short form: data: Velarion
The paid brief for Penumbra
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
16 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Penumbra and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
MedTech & Diagnostics rankings
Peers Penumbra discloses
The companies named in PEN's own disclosed peer group.
10x GenomicsBio-TechneCONMED CorporationGlaukos CorporationGlobus MedicalHaemonetics CorporationInspire Medical SystemsInsulet CorporationInteger HoldingsIntegra LifeSciences HoldingsiRhythm TechnologiesLantheus HoldingsLivaNova PLCMasimo CorporationMedpace HoldingsMerit Medical SystemsNeogen CorporationQuidelOrtho CorporationSotera Health CompanyTandem Diabetes CareTeladoc Health
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}